BioFinance 2011 – Canada’s preeminent investor conference for the life sciences industry – will feature 46 presenting companies this year ranging in market capitalizations from less than $20 million to nearly half a billion dollars.

 Calgary-based Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) comes to the conference riding the momentum from its Phase 3 clinical trial for its oncology asset REOLYSIN®. Ontario-based YM Biosciences (NYSE Amex: YMI, TSX: YM), also an oncology play, will be talking about its Phase 2 cancer product. Both companies will be presenting in the morning on June 1.

 For investors looking for ideas outside of the oncology space, Spectral Diagnostics Inc. (TSX: SDI) management will share details about its Phase 3 theranostic trial for its product candidate that has the potential to assess and treat patients with septic shock. Management from Theratechnologies Inc. (TSX: TH) will be on hand to talk about the company’s FDA-approved drug to treat excess abdominal fat (lipodystrophy) in HIV-infected patients.

 In addition to the corporate presentations, BioFinance 2011 will feature a series of panels involving many of the industry’s key players from the buy and sell side of Bay Street and Wall Street.

 The `Breakfast with Dealmakers’ panel on June 1 features a number of U.S. institutional investors from funds such as Tavistock Life Sciences, Burrill & Co and Merlin Nexus. At noon, the sell side expresses its view in the aptly named `View from Wall Street’ panel when five veteran U.S. investment bankers will discuss strategies for Canadian issuers to make headway in the U.S. marketplace.

Adam Peeler
Senior Account Executive                                                                                                                                                                                                                         Healthcare & Cleantech Group